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INTRODUCTION
Decongestant drugs generally serve as the first-line treatment 
for nasal congestion and all have a-adrenoceptor agonist, i.e. 
sympathomimetic activity. They are marketed as topical and oral 
formulations, aimed to relieve the symptom of nasal congestion, 
commonly seen in upper respiratory viral infections (common 
cold), allergic rhinitis, vasomotor rhinitis and chronic sinusitis. 
Protracted nasal congestion, if untreated, can lead to sequelae 
such as sinusitis or otitis media. Symptoms of nasal congestion, 
especially if associated with vasomotor rhinitis and the common 
cold, can be relieved by the short-term use (usually not longer 
than 5~7 days) of decongestant nasal drops and sprays. It is 
emphasized in the literature that their clinical applicability 
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ABSTRACT Vasoconstrictive properties of sympathomimetic drugs are the basis of 
their widespread use as decongestants and possible source of adverse responses. 
Insufficiently substantiated practice of combining decongestants in some marketed 
preparations, such are those containing phenylephrine and lerimazoline, may affect 
the overall contractile activity, and thus their therapeutic utility. This study aimed 
to examine the interaction between lerimazoline and phenylephrine in isolated rat 
aortic rings, and also to assess the substrate of the obtained lerimazoline-induced 
attenuation of phenylephrine contraction. Namely, while lower concentrations 
of lerimazoline (10–6 M and especially 10–7 M) expectedly tended to potentiate 
the phenylephrine-induced contractions, lerimazoline in higher concentrations 
(10–4 M and above) unexpectedly and profoundly depleted the phenylephrine 
concentration-response curve. Suppression of NO with NO synthase (NOS) inhibitor 
Nw-nitro-L-arginine methyl ester (L-NAME; 10–4 M) or NO scavanger OHB12 (10
–3 M), as 
well as non-specific inhibition of K+-channels with tetraethylammonium (TEA; 10–3 
M), have reversed lerimazoline-induced relaxation of phenylephrine contractions, 
while cyclooxygenase inhibitor indomethacin (10–5 M) did not affect the interaction 
between two vasoconstrictors. At the receptor level, non-selective 5-HT receptor 
antagonist methiothepin reversed the attenuating effect of lerimazoline on 
phenylephrine contraction when applied at 3×10–7 and 10–6 M, but not at the 
highest concentration (10–4 M). Neither the 5-HT1D-receptor selective antagonist BRL 
15572 (10–6 M) nor 5-HT7 receptor selective antagonist SB 269970 (10
–6 M) affected 
the lerimazoline-induced attenuation of phenylephrine activity. The mechanism 
of lerimazoline-induced suppression of phenylephrine contractions may involve 
potentiation of activity of NO and K+-channels and activation of some methiothepin-
sensitive receptors, possibly of the 5-HT2B subtype.
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in states that need prolonged administration is limited due to 
possibility of rebound congestion (rhinitis medicamentosa) on 
withdrawal [1]. 
Phenylephrine is an efficacious a1 receptor adrenergic agonist 
widely used as a nasal decongestant, where its utility has been 
attributed to a1 adrenergic receptor-mediated vasoconstriction 
in nasal mucosa. This sympathomimetic agent is a synthetic 
selective a1-adrenergic agonist with mainly direct rather than 
indirect effects on adrenergic receptors. It was shown that the a1-
adrenoceptor subtype mediating contraction to phenylephrine 
in rabbit corpus cavernosum has the characteristics of the a1B-
adrenoceptor subtype [2]. On the other hand, the results from 
another study, performed by use of antagonists which in binding 
studies show selectivity between the cloned a1-adrenoceptor 
subtypes, suggest that the contraction to phenylephrine of the 
rat thoracic aorta, mesenteric artery and pulmonary artery 
are mediated in part via the a1D-subtype of adrenoceptors [3]. 
Finally, in a similarly designed experiment, it appeared that 
phenylephrine actions in the model of the rabbit cavernous 
artery may be antagonized only by an a1A-adrenergic receptor 
blocker, suggesting that the predominant a1-adrenoceptor 
subtype involved in vasoconstriction of penile arteries was the 
a1A-adrenoceptor [4]. From these pieces of evidence it may be 
concluded that all subtypes of the a1 adrenergic receptor may 
contribute to vascular effects of phenylephrine.
Lerimazoline is a congener of oxymetazoline and xylome-
tazoline which has been used in combination with phenylephrine 
in nasal decongestant preparations for half a century [5]. The 
pharmacological profile of this compound, reported earlier as St-
71, trimizoline or trimazoline, is not sufficiently elucidated in 
the present literature [6-8]. It has been known for some time that 
lerimazoline possesses a substantial affinity for 5-HT1D, and much 
less for 5-HT1B receptors (Ki values 72 vs. 3480 nM) [9]; more 
recently, it was found that it also demonstrates a high affinity for 
5-HT1A receptor (Ki=162.5 nM), while binding affinity estimates 
(Ki) for a1, 5-HT2A and D2 receptors were 6656, 4202 and 3437.5 
nM, respectively [Rizvic et al., manuscript in preparation]. When 
evaluated for contractile activity in the rings of rabbit saphenous 
vein pretreated with all, prazosin, idazoxan and indomethacin, 
in order to exclude possible adrenergic a1, a2 or prostaglandin-
mediated effects, respectively, EC50 of lerimazoline (150 nM) was 
similar to that of the 5-HT1B/D receptor agonist sumatriptan used 
as the positive control (EC50=220 nM) [9]. As it was shown that 
the rabbit saphenous vein did not functionally contract to 5-HT1D 
receptor activation, while the high-affinity 5-HT1B receptor 
antagonist displayed surmountable antagonism of the contractile 
effects of sumatriptan [10], it can be indirectly concluded that 
contractile action of lerimazoline in that blood vessel should 
arise from activation of 5-HT1B receptors. On the other hand, 
our recent results suggested that the lerimazoline-induced 
contractions in rat thoracic aorta, that varied in the range 40~55% 
of the contractions elicited by 10–4 M phenylephrine, may be 
mediated mainly through non- a1 adrenergic receptors, possibly 
of the 5-HT2A subtype [Rizvic et al., manuscript in preparation], 
making it ‘an atypical decongestant’.
Such results were an impetus for assessment of the possible 
influences of lerimazoline on the contractile activity of phenyle-
phrine, with a remote translational hypothesis that an interaction 
between these two vasoconstrictor agents, if revealed, may be useful 
in order to overcome rebound congestion seen on withdrawal 
of decongestants administered as single agents. We opted to 
study the putative interaction in the well-validated [11], and in 
our previous experiments with lerimazoline already used rat 
aorta preparation, having in mind the recognized variability of 
agonist-induced actions in different vascular beds of rats, which 
depend on concentrations tested, type of receptor involved, basal 
vascular tone, vascular bed analyzed and the presence of possible 
pathological processes [12-14].
METHODS
Aorta segments were taken from portions of 250~350 g weighing 
Wistar rats thoracic aorta, obtained from Military farm, Belgrade, 
Serbia. During treatment, rats were housed in clean transparent 
plastic cages with free access to tap water and pelleted food and 
kept in a conventional animal facility at a temperature of 22±1°C, 
relative humidity of 40~70% and the 12/12 h light/dark period, 
with lights on from 06:00. The animal study was performed after 
receiving approval of the Institutional Animal Care and Use 
Committee (approval No. 323-07-09231/2016-05/4, issued by the 
Veterinary Administration of the Republic of Serbia).
Reagents and drugs
Methiothepin hydrochloride (non-selective 5-HT antagonist), 
indomethacin hydrochloride (cyclooxygenase inhibitor), tetrae-
thylammonium (TEA, the nonspecific K+ channel blockers), 
L-NAME (nonspecific NOS inhibitor Nw-nitro-L-arginine methyl 
ester) and prazosin hydrochloride (a1 antagonist) were purchased 
from Sigma Aldrich (St. Louis, MO, USA). SB 269970 (selective 
5-HT7 antagonist), BRL 15572 (selective 5-HT1D antagonist) and 
OHB12 (NO scavenger) were purchased from Tocris (Bristol, UK). 
Lerimazoline hydrochloride and phenylephrine hydrochloride 
were kindly donated from Zdravlje Actavis, Leskovac, Serbia.
All drugs, except indomethacin, were prepared as concen-
trated stocks in distillated water before dilution to the final con-
centration each day and stored at 4°C during the experiment. 
Indomethacin was initially dissolved in 1% DMSO with sub-
sequent dilutions carried out in distillated water. Drug concen-
trations are described as final molar concentrations in the tissue 
bath. 
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Experimental design
Isometric tension in aortic rings: Male Wistar rats were eutha-
nized with carbon dioxide and the thoracic aortas were dissected, 
cleared of connective tissue, and cut into cylindrical segments of 
approximately 3 mm length while the blood vessels were bathed 
in Petri dishes containing modified Krebs-bicarbonate solution 
(KBS) of the following composition: 118.3 mM NaCl, 4.7 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 25 mM NaHCO3, 1.2 mM 
KH2PO4, 11 mM glucose. In a number of vessel preparations, 
the endothelial cell layer was removed by gently rubbing the 
luminal surface of the ring. Two stainless steel triangles were 
passed through the lumen of aortic rings, one of which was fixed 
to the organ bath wall whereas the other one was attached to 
the MLT0201 force displacement transducer (Panlab, Spain), 
mounted on a micrometer for manual adjustment of tension. The 
prepared aortic rings were mounted in a temperature-controlled 
organ baths (37°C) containing 25 ml Krebs solution which was 
continuously gassed with 95% O2 and 5% CO2.
The signal was digitalized using the PowerLab/4SP data acqui-
sition system (AD Instruments, Castle Hill, Australia) and changes 
in isometric tension were recorded with LabChart 6 Pro software 
(AD Instruments). Four organ baths were run in parallel. 
Segments were allowed to equilibrate for 1 h in KBS, during 
which it was replaced every 10 min to prevent accumulation of 
metabolic end-products. During further 20 min, each aortic ring 
was stretched progressively to optimal length of 2 g for maximal 
isometric contraction and additionally was allowed to equilibrate 
for 40 min before commencing the experiment. In those protocols 
involving consecutive obtainment of two or three concentration-
response curves, after completion of the previous concentration-
response curve, the response was terminated by exchanging the 
KBS every 10 min for 30 min, thus allowing the aortic rings to 
return to their baseline tension. Each segment of rat aorta was 
used only for one experimental protocol.
Experimental protocol: The first series of experiments were 
aimed to measure constrictive strength of two agonists, and 
consisted of two parts performed in separate aorta rings. First, 
concentration-response curves of phenylephrine were generated 
by adding it to the organ bath in cumulative concentrations 
(10–8~10–4 M). Second, concentration-response curves of lerima-
zoline were constructed by adding it to the organ bath in cumu-
lative concentrations (10–7~3×10–4 M) and after washout, the 
contraction strength induced by 10–4 M phenylephrine was 
measured. Cumulative concentration-response curves were 
generated by increasing the concentration of phenylephrine or 
lerimazoline in half-log increments, once the constriction to the 
previous concentration had stabilized [15,16].
The second series of experiments were aimed at assessing 
the effect of lerimazoline on contractile response induced by 
phenylephrine in aorta rings. Twenty min after obtaining the 
cumulative phenylephrine-induced contraction curve and washing 
out, lerimazoline was added directly to the organ bath. The 
effect of lerimazoline (2.1×10–3 M, 10–4, 10–6 or 10–7 M) on the 
concentration response curves for phenylephrine (10–8 to 10–5 
M, with exception for the highest concentration of lerimazoline, 
where phenylephrine was used in concentration range 10–8 to 10–2 
M) was assessed by comparing the contractile response in the 
absence or presence of lerimazoline. 
In the third series of experiments, in order to evaluate the 
mechanism(s) responsible for lerimazoline-induced attenuation 
of the contractile response evoked by phenylephrine, each 
equilibrated rat aorta was first constricted by incremental 
concentrations of phenylephrine (10–8~10–4 M). The effect of 
pretreatment with nonspecific NOS inhibitor Nw-nitro-L-
arginine methyl ester L-NAME (10–4 M), NO scavanger OHB12 
(10–3 M), non-specific K+ channel blocker tetraethylammonium 
(10–3 M), cyclooxygenase inhibitor indomethacin (10–5 M), non-
selective 5-HT antagonist methiothepin (10–4, 10–6 M or 3×10–7 
M), selective 5-HT7 antagonist SB 269970 (10–6 M) or selective 
5-HT1D antagonist BRL 15572 (10–6 M), on the concentration-
response curve for phenylephrine was assessed by measuring 
the contractile response in the absence and presence of 10–4 M 
lerimazoline, respectively. The experiments without lerimazoline 
were performed in those cases where the respective inhibitor/
antagonist has previously affected the putative interaction bet-
ween phenylephrine and lerimazoline.
Throughout the experiment, the constriction strength was 
expressed as a percentage of the maximum tension induced by 
the highest concentration of phenylephrine used in the given 
protocol.
Data analysis
Contractions produced by phenylephrine, lerimazoline or 
different antagonists/inhibitors on their own were measured as 
changes in tension from baseline (i.e. the tension immediately 
before the respective agonist administration) and expressed as 
a percentage of the phenylephrine maximum (mean±S.E.M). 
Agonist potency expressed as an EC50 (the molar concentration 
necessary to produce 50% of the maximum agonist response) 
and maximum response (Emax) were determined from individual 
concentration-response curves by non-linear regression analysis.
In experiments with combined administration, EC50 values of 
phenylephrine obtained in the presence and absence of lerima-
zoline or the used inhibitor/antagonist were compared by an 
unpaired t-test. An analysis of variance was used to compare EC50 
values and maximum responses obtained with phenylephrine, as 
well as phenylephrine and lerimazoline in the presence or absence 
of an inhibitor/antagonist. When the ANOVA indicated that 
differences existed between groups, Tukey’s multiple-comparison 
test was applied to determine the source of variation [17]. The 
n values refer to the number of aorta vessels tested. Statistical 
significance was accepted at p<0.05. 
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RESULTS
Vascular responses to phenylephrine or lerimazoline
The agonists used in this study exhibited different contractile 
activity in rat thoracic aortas, irrespective of presence of endo-
thelium. The addition of lerimazoline to the isolated tissues 
produced virtually no change in isometric tension over the 
concentration range of 10–7~10–5 M. For higher doses, in the range 
10–5~3×10–4 M, lerimazoline produced the maximal response of 
about 45% of the response induced by 10–4 M phenylephrine, with 
pEC50=4.20 (Fig. 1). Specifically, phenylephrine started to increase 
tension from the first concentration of the drug tested (10–8 M), 
with the pEC50=5.77. Fig. 1. Comparison of the contractile effect of phenylephrine (n=12) 
and lerimazoline (n=12) on rat thoracic aorta. Data are shown 
as mean±S.E.M, expressed for phenylephrine as the percentage of 
maximum contraction induced by maximum dose of phenylephrine, 
and for lerimazoline as the percentage of maximum contraction 
induced by 10–4 M phenylephrine.
Fig. 2. Vascular responses to phenylephrine in blood vessels exposed to different concentrations of lerimazoline. (A) Concentration-response 
curves for phenylephrine in the absence (•, n=7) and in the presence of lerimazoline 2.1×10–3 M (º, n=7). (B) Concentration–response curves for 
phenylephrine in the absence (•, n=10) and in the presence of lerimazoline 10–4 M (º, n=10). (C) Concentration–response curves for phenylephrine 
in the absence (•, n=10) and in the presence of lerimazoline 10–6 M (º, n=10). (D) Concentration–response curves for phenylephrine in the absence 
(•, n=9) and in the presence of lerimazoline 10–7 M (º, n=9). Results (means±S.E.M) were expressed as percentages of the response to the 10–4 M 
phenylephrine. *p<0.05, **p<0.01 vs. the effect of the respective concentration of phenylephrine.
Unusual antagonism of phenylephrine contraction
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Vascular responses to phenylephrine in blood vessels 
exposed to different concentrations of lerimazoline
A quantitative comparative study was conducted to examine 
the effect of lerimazoline on response to phenylephrine. Higher 
concentrations of lerimazoline (2.1×10–3 M and 10–4 M) highly 
significantly attenuated maximal response (p<0.001) of phenyle-
phrine concentration-response curve (Emax=100±0.00% and 
8.78±2.47%; pEC50 being 5.46±0.31 and 3.06±0.72, p<0.05, 
for phenylephrine alone and with lerimazoline 2.1×10–3 M, 
respectively, Fig. 2A; and Emax=100±0.00% and 9.91±4.58%; pEC50 
being 5.60±0.17 and 5.23±0.23, p>0.05, for phenylephrine alone 
and with lerimazoline 10–4 M, respectively, Fig. 2B). However, 
in tissue precontracted with lerimazoline (10–6 and 10–7 M), 
phenylephrine produced vasoconstrictor responses which were 
markedly more prominent then those observed in previous 
preparations, containing high concentrations of lerimazoline. 
Indeed, the lower concentrations of lerimazoline (10–6 and 10–7 M) 
produced a significant potentiation of the phenylephrine-induced 
contractions (Fig. 2C, D), with fine differences between the effects 
of two concentrations. While lerimazoline (10–7 M) produced a 
potentiation of the phenylephrine-induced contractions starting 
from the lowest concentration of phenylephrine (Emax from 
100±0.00% in the absence to 168.10±21.40% in the presence of 
lerimazoline, Fig. 2D, p<0.01) without significant change in pEC50 
(6.11±0.20 control vs 5.92±0.27 in the presence of lerimazoline), 
a significant increase in maximum response of phenylephrine-
evoked vasoconstriction by lerimazoline (10–6 M) occurred only 
at phenylephrine concentrations of 3×10–6 M and 1×10–5 M (Fig. 
2C; p<0.05 at 3×10–6 M and p<0.001 at 1×10–5 M). Moreover, the 
vasoconstrictive effects of lower concentrations of phenylephrine 
tended to be counteracted by lerimazoline, a significant decrease 
being observed at 3×10–7 M of phenylephrine. The Emax value 
was 100±0.00% in the absence vs 139.99±10.65% in presence of 
lerimazoline at the concentration of 1×10–6 M, p<0.01, with a 
significant change in pEC50 (5.60±0.29 control vs 4.62±0.27, p< 
0.05).
Vascular responses to phenylephrine in presence of 
10–4 lerimazoline and different inhibitors/antagonists
In order to elucidate the mechanistic substrate for an un-
precedented antagonism of contractile actions of phenylephrine 
exerted by lerimazoline, we chose to test the increasing concen-
trations of phenylephrine in presence of various ligands in two 
protocols: in the absence and presence of 10–4 M lerimazoline. The 
pEC50 values of combination of phenylephrine and lerimazoline 
obtained in the absence and presence of the given concentration 
of ligand, together with the respective number of blood vessel 
preparations, are given in Table 1.
Effects of L-NAME and OHB12 on the vasoconstrictor 
responses induced by phenylephrine and 
lerimazoline
A quantitative comparative study was performed with the goal 
to examine the effect of L-NAME (10–4 M) and OHB12 (10–3 M) 
on responses to phenylephrine in the absence and presence of 
lerimazoline (10–4 M). Primary, L-NAME potentiated the Emax to 
phenylephrine in thoracic aorta rings. The maximal contraction 
pretreated with L-NAME increased from 100% to 163.38±21.06% 
(Fig. 3A; *p<0.05). Lerimazoline (10–4 M) caused a significant 
decrease (***p<0.001, Student’s unpaired t-test) in the maximum 
contraction response to phenylephrine from 100% to 55.95±6.47%. 
The non-selective inhibitor of NO synthesis L-NAME completely 
reversed the lerimazoline-induced attenuation of the contractile 
effect of higher doses of phenylephrine. Under these conditions 
L-NAME increased significantly the maximum contractions 
of phenylephrine pretreated with lerimazoline (10–4 M) from 
Table 1. Effect of L­NAME, OHB12, indomethacin, TEA, SB 269970, 
BRL 15572 and methiothepin on pEC 50 obtained against 
contractions induced by phenylephrine in the presence of 10–4 M 
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Values are means±S.E.M.; pEC50 is the negative log of pheny-
lephrine concentrations producing 50% of maximum response. 
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55.95±6.47% to 84.59±10.49% (Fig. 3B; #p<0.05,). OHB12 
potentiated the Emax to phenylephrine in thoracic aorta rings 
from 100% to 155.25±11.76% (Fig. 3C; **p<0.01). The maximum 
response to phenylephrine pretreated with lerimazoline was also 
significantly increased from 49.18±10.25% to 101.53±12.49% in 
the presence of OHB12 (Fig. 3D; ##p<0.01).
Effects of indomethacin and TEA on the 
vasoconstrictor responses induced by phenylephrine 
and lerimazoline
The interaction between phenylephrine and lerimazoline was 
examined in the presence of indomethacin or tetraethylam-
monium (TEA). While the cyclooxygenase inhibitor indome-
thacin (10–5 M) did not change the basal tone of the vessels 
pretreated with lerimazoline (Fig. 4A; p>0.05), TEA (10–3 M), a 
non-specific inhibitor of K+ channels, potentiated the effect of 
phenylephrine in the thoracic aorta pretreated with lerima-
zoline. Namely, while TEA did not significantly affect the 
maximal response to phenylephrine in thoracic aorta rings 
(Fig. 4B), it increased significantly the maximum contractions 
of phenylephrine pretreated with lerimazoline (10–4 M), from 
59.56±8.53% to 103.32±11.31% (Fig. 4C; ##p<0.01).
Effects of methiothepin on the vasoconstrictor 
responses induced by phenylephrine and 
lerimazoline
The sensitivity of the interaction of phenylephrine and 
lerimazoline to antagonism by methiothepin was evaluated 
using three antagonist concentrations (10–4, 10–6 and 3×10–7 
M). Methiothepin (10–4 M) caused complete amelioration in 
tension of phenylephrine induced contraction of rings pretreated 
with lerimazoline (Emax: 62.49±13.58% in presence of 10–4 M 
Fig. 3. Effects of L­NAME and OHB12 on the vasoconstrictor responses induced by phenylephrine and lerimazoline. (A) Effect of 10–4 M 
L-NAME on the phenylephrine concentration response curve in rings without 10–4 M lerimazoline. (B) Effect of 10–4 M L-NAME on the phenylephrine 
concentration response curve in rings pretreated with 10–4 M lerimazoline. (C) Effect of 10–3 M OHB12 on the phenylephrine concentration response 
curve in rings without 10–4 M lerimazoline. (D) Effect of 10–3 M OHB12 on the phenylephrine concentration response curve in rings pretreated with 10
–4 
M lerimazoline.Results (means±S.E.M) were expressed as percentages of the response to the 10–4 M phenylephrine. *p<0.05, **p<0.01, ***p<0.001 vs. 
phenylephrine; #P<0.05, ##p<0.01, ###p<0.001 vs. phenylephrine plus lerimazoline.
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lerimazoline vs 13.94±6.52% in presence of 10–4 M lerimazoline 
plus 10–4 M methiothepin Fig. 5A, ##p<0.01). The response to 
phenylephrine in aortic segments untreated with lerimazoline 
was significantly inhibited by methiothepin at 10–6 M (Fig. 5B, 
p<0.05), but not at a lower concentration (3×10–7 M) (Fig. 5D). On 
the contrary, in the presence of lower concentrations of methio-
thepin (10–6 and 3×10–7 M), concentration response curve to 
phenylephrine pretreated with lerimazoline was increased at the 
last three concentrations of phenylephrine concentration response 
curve (Emax: 59.24±10.42% in presence of 10–4 M lerimazoline 
vs 87.08±14.83% in presence of 10–4 M lerimazoline plus 10–6 
M methiothepin, Fig. 5C; 48.68±3.73% in presence of 10–4 M 
lerimazoline vs 74.42±11.27% in presence of 10–4 M lerimazoline 
plus 3×10–7 M methiothepin, Fig. 5E; #p<0.05).
Effects of SB 269970 and BRL 15572 on the 
vasoconstrictor responses induced by phenyephrine 
and lerimazoline
The interaction between phenylephrine and lerimazoline 
was examined in the presence of higly selective 5-HT7 receptor 
antagonist SB 269970 (Fig. 6A) and selective 5-HT1D receptor 
antagonist BRL 15572 (Fig. 6B). Results have shown that neither 
SB 269970 (10–6 M) nor BRL 15572 (10–6 M) did change the basal 
tone of the vessels pretreated with lerimazoline (47.89±5.52% 
in presence of 10–4 M lerimazoline vs 45.24±5.42% in presence 
of lerimazoline plus 10–6 M SB 269970, p>0.05; 62.08±16.01% in 
presence of 10–4 M lerimazoline vs 58.76±11.74% in presence of 
lerimazoline plus 10–6 M BRL 15572, p>0.05). 
DISCUSSION
Our study revealed that there is an intricate interaction bet-
ween phenylephrine, a strong vasoconstrictor selective for a1 
adrenergic receptors, and lerimazoline, an imidazoline ligand 
Fig. 4. Effects of indomethacin and TEA on the vasoconstrictor responses induced by phenylephrine and lerimazoline. (A) Effect of 10–5 
M indomethacin on the phenylephrine concentration response curve in rings pretreated with 10–4 M lerimazoline. (B) Effect of 10–3 M TEA on the 
phenylephrine concentration response curve in rings without 10–4 M lerimazoline. (C) Effect of 10–3 M TEA on the phenylephrine concentration 
response curve in rings pretreated with 10–4 M lerimazoline. Results (means±S.E.M) were expressed as percentages of the response to the 10–5 M 
phenylephrine. *p<0.05, **p<0.01, ***p<0.001 vs. phenylephrine; #p<0.05, ##p<0.01 vs. phenylephrine plus lerimazoline.
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whose moderate vasoconstrictor actions have been related more 
to activation of 5-HT1B [9] or 5-HT2A [Rizvic et al., manuscript 
in preparation], than a1 adrenergic receptors. While lower 
concentrations of lerimazoline (10–6 or 10–7 M) tended to poten-
tiate the vasoconstrictor activity of phenylephrine, lerimazoline 
in higher concentrations (10–4 M and above) unveiled the poten-
tial to profoundly suppress the phenylephrine-induced vasocon-
striction. The latter action was totally unexpected and asked for 
Fig. 5. Effects of methiothepin on the vasoconstrictor responses induced by phenylephrine and lerimazoline. (A) Effect of 10–4 M 
methiothepin on the phenylephrine concentration response curve in rings pretreated with 10–4 M lerimazoline. (B) Effect of 10–6 M methiothepin 
on the phenylephrine concentration response curve in rings without 10–4 M lerimazoline. (C) Effect of 10–6 M methiothepin on the phenylephrine 
concentration response curve in rings pretreated with 10–4 M lerimazoline. (D) Effect of 3×10–7 M methiothepin on the phenylephrine concentration 
response curve in rings without 10–4 M lerimazoline. (E) Effect of 3×10–7 M methiothepin on the phenylephrine concentration response curve in 
rings pretreated with 10–4 M lerimazoline. Results (means±S.E.M.) were expressed as percentages of the response to 10–4 M phenylephrine. *p<0.05, 
**p<0.01, ***p<0.001 vs. phenylephrine; #p<0.05, ##p<0.01 vs. phenylephrine plus lerimazoline.
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further elucidation.
Potentiation of phenylephrine-induced contractions by low 
lerimazoline concentrations could be explained as follows: 
pheny lephrine activated its a1 receptors on vascular smooth 
muscle cells and exhibited potent vasoconstrictor effects, while 
lerimazoline may potentiated that action by eliciting additional 
contractile effects related to activation of 5-HT1B [9] and/or 
5-HT2A receptors. On the other hand, it is not possible to propose 
a parsimonious explanation for the antagonistic action of higher 
concentrations of lerimazoline on contraction of rat aorta 
produced by phenylephrine. It has been noticed that cumulative 
addition of 10–4 M lerimazoline (a concentration that significantly 
attenuated phenylephrine concentration-response curve), induced 
contraction of rat aorta of about 20% of the response induced by 
10–4 M phenylephrine ([5]; the present results), while a one-time 
addition of the same lerimazoline concentration did not induce 
any change in the tone of the same vessel (the present results). 
However, in the latter, but not the former case, lerimazoline 
was added into organ bath after obtaining the cumulative 
phenylephrine-induced contraction curve and washing out, and 
in such settings a kind of homologous (related to a1 adrenergic 
receptors) or, more probably, heterologous (related to distinct 
subtypes of 5-HT receptors) desensitization, demonstrated and 
described in detail in rabbit aorta exposed to norepinephrine and 
angiotensin II [18], could have taken its place.
Two main questions to be addressed are related to molecular 
messengers and receptor substrates of the observed attenuation 
of phenylephrine-induced rat aorta contraction achieved by 
lerimazoline, as a vasoconstrictive, rather than vasodilatory, agent 
on its own. Endothelium plays an important role in the regulation 
of vasoconstriction and vasodilation response elicited by different 
agonists. It releases vasodilatator factors, i.e. NO, EDHF and 
prostacyclin, as well as vasoconstrictor factors, i.e. endothelin 
1, COX-derived vasoconstrictor products and superoxide anion 
[19,20]. While NO inhibits the contractile response to many 
vasoconstrictors [21,22], EDHF causes endothelium-dependent 
hyperpolarization and relaxation in the rat aorta by opening K+ 
channels, which cannot be overcome by the full blockade of NOS 
and cyclooxigenase [21]. As we used both, endothelium intact 
and denuded rings and the vascular activity of phenylephrine 
and lerimazoline, on their own and in combination, was 
unaffected by presence or absence of endothelium, it could be 
supposed that modulation of endothelial-derived vasoactive 
factors would not dominantly change the blood vessel reactivity 
to them. Nevertheless, the possibility of involvement of endoge-
nously produced NO or prostaglandins in the mediation of 
phenylephrine – lerimazoline interaction was studied in the 
presence of the NO inhibitors L-NAME and OHB12 or cyclooxy-
genase inhibitor indomethacin, respectively. In addition, we 
investigated the influence of non-selective K+ inhibitor tetrae-
thylammonium on attenuation of phenylephrine-induced con-
traction induced by lerimazoline. Lastly, the place of the 5-HT 
receptor pathway in the observed interaction was assessed using 
the highly selective 5-HT1D receptor antagonist BRL 15572, 5-HT7 
receptor antagonist SB 269970 and non-selective 5-HT receptor 
antagonist methiothepin.
Pretreatment with L-NAME or OHB12 reduced the lerima-
zoline-induced attenuation of the maximal contractile re-
sponse to phenylephrine. This effect may be at least partially 
correlated via the NO-mediated modulation by lerimazoline 
of the phenylephrine contraction. However, assessment of 
relative contribution of this mechanism to the overall action of 
lerimazoline is hampered by the fact that both, L-NAME and 
OHB12 significantly potentiated the phenylephrine contraction 
Fig. 6. Effects of SB 269970 and BRL 15572 on the vasoconstrictor responses induced by phenyephrine and lerimazoline. (A) Effect of 10–6 
M SB 269970 on the phenylephrine concentration response curve in rings pretreated with 10–4 M lerimazoline. (B) Effect of 10–6 M BRL 15572 on the 
phenylephrine concentration response curve in rings pretreated with 10–4 M lerimazoline. Results (means±S.E.M) were expressed as percentages of 
the response to 10–4 M phenylephrine. *p<0.05, **p<0.01, ***p<0.001 vs. phenylephrine; #p<0.05, ##p<0.01 vs. phenylephrine plus lerimazoline.
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on its own. On the other hand, the opening of K+ channels in 
vascular smooth muscle cells triggers membrane potential 
hyperpolarization and thus provides an important mechanism 
to prevent blood vessel contraction, the activities of certain K+-
channels are inhibited by the non-selective blocker TEA. The 
opening of K+ channels is probably activated by lerimazoline 
irrespective of phenylephrine, since there was no significant 
potentiation in the phenylephrine concentration-response curve 
pretreated with TEA. The described pattern of possible signaling 
mechanisms is not unique; as an example, a similar pattern 
was reported for amfepramone (diethylpropion), an appetite-
suppressant drug with incompletely elucidated receptor/
channel binding profile, but with a substantial difference that 
amfepramone on its own tended to relax rather than contract rat 
aortic rings [23].
In regard to the receptor pathways involved in the lerimazoline 
functional antagonism of the phenylephrine-induced rat aorta 
contraction, we concentrated on the 5-HT7 receptor. Namely, 
it is well documented that 5-HT exerts a major part of its 
vasodilatory potential by activation of 5-HT7 receptors, which 
can be prevented by use of the selective antagonist SB 269970. 
As an example, it is shown that 5-HT directly relaxes the rat 
superior mesenteric veins primarily through activation of the 
5-HT7 receptor [24]. Moreover, 5-HT was able to exert direct 
relaxant responses in canine basilar and middle cerebral arteries 
via the same, 5-HT7 receptors [25]. On the other hand, BRL 
15572, as the selective antagonist at the 5-HT1D receptor, was 
used as a kind of negative control, having in mind that the canine 
external carotid vasodilator responses remained unaffected in 
presence of this ligand [26]. However, it appeared that not only 
the 5-HT1D, but also the 5-HT7 receptor was not involved in 
relaxant influences of lerimazoline. Nevertheless, the experiment 
with methiothepin gave a hint about the receptor substrate of the 
relaxant potential of lerimazoline. Namely, while methiothepin 
at 10–4 M did not affect the action of lerimazoline, methiothepin 
at 10–6 and 3×10–7 M significantly reversed the lerimazoline-
induced attenuation of the phenylephrine concentration-
response curve, the lower concentration of methiothepin being 
devoid of the potential to interact with phenyleprine. If we 
assume that methiothepin in low concentrations did bind only to 
those receptors for which possesses the highest affinity, we can 
postulate that the 5-HT2B subtype, to which methiothepin has Ki 
in the range 8.7~9.2 (IUPHAR database), was the first receptor 
blocked with methiothepin, significantly increasing in turn the 
contractile action of the blood vessel exposed to phenylephrine 
and lerimazoline in combination. This is in accordance with 
findings that 5-HT2B receptors are located on the endothelial cell 
and, when activated, stimulate NO release [27]. Moreover, it was 
demonstrated that treatment with 5-HT2B receptor antagonist 
abolishes a bypass-induced fall in blood pressure in Wistar rat in 
vivo [28]. It is worth to note that the second in a row binding site 
for methiothepin is the 5-HT7 receptor (with Ki value in the range 
8.4~9.4) (IUPHAR database), which suggests once more that the 
5-HT2B receptor is the probable receptor substrate of the relaxant 
actions of lerimazoline; however, further work is necessary before 
definite assignments can be made.
Finally, it shall be commented that the seemingly paradoxical 
pattern of actions of lerimazoline, with its moderate contractile 
activity, but also a capability to suppress the contraction induced 
by another, more effective contractile agent, should not be 
regarded as totally unprecedented. As an important example, 
Lamarre et al. [29] have reported that cocaine can exhibit both 
vasoconstricting and vasorelaxant effects. In fact, at a concen-
tration devoid of effects on its own, cocaine potentiated the vaso-
constriction produced by norepinephrine, as well the a1-selective 
agonists phenylephrine and methoxamine. On the other hand, 
higher concentrations of cocaine in combination with adrenergic 
agonists exerted a concentration-related relaxation, i.e. gave an 
inverted-U shaped (hormetic) dose–effect curve. The authors 
postulated that the relaxing component of the effect was due to 
activation of myosin light chain phosphatase by cocaine, shown 
by Li et al. [30].
In conclusion, the present results indicate that the presence 
of lerimazoline, at a concentration close to and above that of 
phenylephrine, may result in the level of vasoconstriction less 
pronounced than that obtained with either of agents alone. In 
can be hypothesized that the interaction of lerimazoline with 
phenylephrine as one of standard decongestants, effected through 
receptor and signaling mechanisms probably involving the 
substrates other than the a1 adrenergic receptor, may suppress 
or slow down the development of the rebound congestion, which 
needs further research and assessment in clinical settings.
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